The RESILIENCE clinical trial has been designed to explore the effectiveness and safety of remote ischemic conditioning (RIC) used to prevent the cardiotoxic effects of anthracycline-based chemotherapy in patients with lymphoma.
from Medical Xpress - latest medical and health news stories https://ift.tt/vETLBd9
